Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
183 hedge funds and large institutions have $2.57B invested in Acceleron Pharma in 2019 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 61 increasing their positions, 60 reducing their positions, and 19 closing their positions.
96% more call options, than puts
Call options by funds: $20.4M | Put options by funds: $10.4M
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
35% more capital invested
Capital invested by funds: $1.9B → $2.57B (+$668M)
6% more funds holding
Funds holding: 172 → 183 (+11)
2% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$91.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$42.6M |
| 3 |
HM
HealthCor Management
New York
|
+$14.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.1M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$6.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$20.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$18.2M |
| 3 |
Alkeon Capital Management
New York
|
-$16.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$13.7M |
| 5 |
AG
Artal Group
Luxembourg
|
-$13.7M |
XLRN Hedge Fund Activity: Q4 2019 in Review
183 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2019, worth a combined $2.57B — up 35% from $1.9B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new XLRN positions and 19 closed out — a net gain of 16 holders — while 61 added to existing stakes and 60 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $91.9M. The largest seller was Great Point Partners, cutting an estimated $20.7M.
- 183 institutional investors held Acceleron Pharma (XLRN) as of Q4 2019, up from 172 in Q3 2019.
- Funds reported $2.57B of Acceleron Pharma stock for Q4 2019, up 35% quarter-over-quarter.
- 35 funds opened new Acceleron Pharma positions in Q4 2019 and 19 closed out, a net change of +16 holders.
- The largest Acceleron Pharma buyer in Q4 2019 was Fidelity Investments, an estimated $91.9M added.
- The largest Acceleron Pharma seller in Q4 2019 was Great Point Partners, an estimated $20.7M sold.
Based on aggregated 13F filings for Q4 2019.